Literature DB >> 22236184

Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.

Judd W Moul1, Nancy Dawson.   

Abstract

The development of new therapies for castration-resistant prostate cancer (CRPC) has increasingly focused on improving patient quality of life, mainly because of limited survival gains and continuing high morbidity burden from disease progression or the adverse effects of treatments. However, there is no generally accepted quality of life instrument for use with this patient group. This paper objectively reviews the existing literature and assesses the impact of CRPC treatments on patients' quality of life. The review also provides a narrative description of the evolving role of quality of life measures in clinical trials, and critiques the most widely used instruments.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22236184     DOI： 10.3109/07357907.2011.629381

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  11 in total

1.  Thrombomodulin mediates the migratory ability of hormone-independent prostate cancer cells through the regulation of epithelial-to-mesenchymal transition biomarkers.

Authors:  Chun-Te Wu; Yu-Jia Chang; Miao-Fen Chen; Jun-Jen Liu; Po-Li Wei; Weu Wang; Hui-Hsiung Liu
Journal:  Tumour Biol       Date:  2014-03-15

Review 2.  Quality-of-life assessment tools for men with prostate cancer.

Authors:  Jonathan Bergman; Aaron Laviana
Journal:  Nat Rev Urol       Date:  2014-05-20       Impact factor: 14.432

3.  Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.

Authors:  Chiachien Jake Wang; James Ying; Payal Kapur; Bryan Wohlfeld; Claus Roehrborn; Dong W Nathan Kim
Journal:  Oncol Lett       Date:  2015-11-18       Impact factor: 2.967

4.  Health-related quality of life in long-term Caribbean prostate cancer survivors: comparisons with prostate cancer-free men.

Authors:  Maria D Jackson; Evelyn Walker; Marshall K Tulloch-Reid
Journal:  Qual Life Res       Date:  2022-07-28       Impact factor: 3.440

Review 5.  Patient-reported outcomes in metastatic castration-resistant prostate cancer.

Authors:  Lesley Fallowfield; Heather Payne; Valerie Jenkins
Journal:  Nat Rev Clin Oncol       Date:  2016-06-28       Impact factor: 66.675

6.  Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.

Authors:  Michael Brundage; Matthew R Sydes; Wendy R Parulekar; Padraig Warde; Richard Cowan; Andrea Bezjak; Peter Kirkbride; Matthew Parliament; Clare Moynihan; Jean-Paul Bahary; Mahesh K B Parmar; Karen Sanders; Bingshu E Chen; Malcolm D Mason
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

7.  Is the bench getting closer to the bedside in the war on cancer? A quick look at prostate cancer.

Authors:  Robert Kypta; Miguel Unda; Arkaitz Carracedo
Journal:  Front Endocrinol (Lausanne)       Date:  2012-04-12       Impact factor: 5.555

8.  Prognostic value of changes in quality of life scores in prostate cancer.

Authors:  Digant Gupta; Donald P Braun; Edgar D Staren
Journal:  BMC Urol       Date:  2013-07-10       Impact factor: 2.264

9.  Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner.

Authors:  Robert M Taylor; Laurel O Sillerud
Journal:  Int J Nanomedicine       Date:  2012-08-06

10.  17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.

Authors:  Zhiyuan Lin; Ruixian Peng; Zhenyu Li; Yang Wang; Chunhua Lu; Yuemao Shen; Jifeng Wang; Guowei Shi
Journal:  Int J Mol Med       Date:  2015-06-09       Impact factor: 4.101
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.